Report error Found 2120 Enz. Inhib. hit(s) with Target = 'Ectonucleotide pyrophosphatase/phosphodiesterase family member 1'
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.00600nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.00600nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.00800nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.00900nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0150nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0160nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0180nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0240nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: <0.0270nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0270nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0290nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0290nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0290nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0350nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0360nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0440nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0520nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0540nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0600nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0620nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0630nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0670nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0720nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0810nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0860nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Inhibition of human recombinant ENPP1 expressed in HEK293T cells using cGAMP as substrate at pH 7.5 measured after 3.5 hrs in presence of ATP by lumi...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.0980nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.103nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.106nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.109nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.138nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.158nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataIC50: 0.160nMAssay Description:Inhibition of human recombinant ENPP1 expressed in HEK293T cells using cGAMP as substrate at pH 7.5 measured after 3.5 hrs in presence of ATP by lumi...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.165nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.167nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics
US Patent
Volastra Therapeutics
US Patent
Affinity DataKi: 0.190nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
